Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Karyopharm Therapeutics

Explore full profile

Karyopharm Therapeutics Inc. is an oncology-focused biopharmaceutical company focused on the discovery, development and commercialization of novel medicines

Newton, United StatesFounded 2008Biotech & Life Sciences
Valuation $20M Market cap · 2026
Revenue $138M Latest reported FY

About Karyopharm Therapeutics

Karyopharm Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines aimed at improving the lives of patients with cancer and other major diseases. The company operates in the biopharmaceutical market, focusing on both hematologic malignancies and solid tumors. Karyopharm's business model revolves around the research and development of novel drugs, with a strong emphasis on targeting nuclear export in cancer cells. This approach involves inhibiting the export of key proteins from the nucleus of cancer cells, thereby inducing cell death and reducing tumor growth. Karyopharm generates revenue through the commercialization of its proprietary drugs, partnerships, and collaborations with other research institutions and pharmaceutical companies. The company's clients primarily include healthcare providers, hospitals, and cancer treatment centers.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2008
Headquarters
Newton, United States
Listing
IPO 2013
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A7 investors entered at this stage

  • Delphi Ventures
  • Adage Capital
  • Foresite Capital
  • Highbridge Capital Management
  • Davidson Kempner Capital Management
  • Braidwell
  • Context Capital Management

Series B and later6 investors entered at this stage

  • Citadel
  • HealthCor Partners
  • Rubric Capital Management
  • Marshall Wace
  • SilverArc Capital
  • HealthCare Royalty
Employees mapped 320 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 33 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States97.5%
🇮🇱 Israel1.3%
🇨🇦 Canada0.4%
🇮🇹 Italy0.4%
🇿🇦 South Africa0.4%
5 countries shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States76.4%
🇮🇳 India9.1%
🇨🇦 Canada7.3%
🇯🇵 Japan2.7%
Top 4 markets shown

Patents

Estimated portfolio value
$67M

35 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Karyopharm Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Karyopharm Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.